Indacaterol/mometasone

Indacaterol/mometasone, sold under the brand name Atectura Breezhaler among others, is a fixed-dose combination medication for the treatment of asthma in adults and adolescents twelve years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2 agonists.[1]

Indacaterol/mometasone
Combination of
IndacaterolBeta-2 adrenergic receptor agonist
MometasoneCorticosteroid
Clinical data
Trade namesAtectura Breezhaler, Bemrist Breezhaler
Other namesQMF149, IND/MF
License data
Routes of
administration		Inhalation
ATC code
Legal status
Legal status
  • EU: Rx-only
  • In general: ℞ (Prescription only)

The most common side effects include worsening of asthma and nasopharyngitis (inflammation in the nose and throat).[1] Other common side effects include upper respiratory tract infection (nose and throat infections) and headache.[1] Indacaterol/mometasone was approved for medical use in the European Union in May 2020,[1] and in Japan in June 2020.[2]

References
  1. "Atectura Breezhaler EPAR". European Medicines Agency (EMA). 24 March 2020. Retrieved 23 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. "Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options". Novartis (Press release). 29 June 2020. Retrieved 25 July 2020.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.